Market capitalization | $1.50b |
Enterprise Value | $511.51m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 54.77 |
P/S ratio (TTM) P/S ratio | 160.93 |
P/B ratio (TTM) P/B ratio | 1.48 |
Revenue growth (TTM) Revenue growth | 28.12% |
Revenue (TTM) Revenue | $9.34m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
13 Analysts have issued a Janux Therapeutics Inc forecast:
13 Analysts have issued a Janux Therapeutics Inc forecast:
Mar '25 |
+/-
%
|
||
Revenue | 9.34 9.34 |
28%
28%
|
|
Gross Profit | 7.29 7.29 |
39%
39%
|
|
EBITDA | -112 -112 |
57%
57%
|
EBIT (Operating Income) EBIT | -114 -114 |
56%
56%
|
Net Profit | -78 -78 |
40%
40%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Janux Therapeutics, Inc. operates preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in La Jolla, CA.
Head office | United States |
CEO | David Campbell |
Employees | 81 |
Founded | 2017 |
Website | www.januxrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.